No Relocation. You are reminded that this Funding is granted under Future Investment Program (section: “Business cluster research and development projects”) and that, as such, among the criteria in the project selection process are included the economic impact of this program for the national territory in terms of added value, particularly in terms of industrial plants and jobs. Consequently, the Beneficiary undertakes, until extinction of the obligations hereunder, to inform Bpifrance in advance by registered letter with acknowledgment of receipt, if possible within [**] days, of any event that may change and or transfer all or part of the production and/or operation of the program outside French territory. This letter will be accompanied by a note indicating the impact of said change(s) on the production and operation of the program. On the basis of these documents, supplemented where relevant by all elements likely to throw light on it, Bpifrance will study the impact of the abovementioned changes. Bpifrance will rule, in the light of the documentation provided by the Beneficiary: • Either that these changes do not alter substantially and significantly the expected economic impacts, so that the condition relating to the selection criterion set out above can be regarded as fulfilled. As necessary, however, Bpifrance may be compelled to redefine and adapt accordingly the terms of payment for Funding and the Financial Returns. This decision will then be a rider to this agreement. • Or that these changes alter substantially and significantly the expected economic impacts, so that the selection criterion condition is no longer fulfilled. Consequently, Bpifrance will apply the provisions of article 2.13 above. [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
Appears in 2 contracts
Sources: Master Agreement (Gensight Biologics S.A.), Master Agreement (Gensight Biologics)